The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation
Key result
Heterozygous carriers of the G20210A prothrombin gene mutation had a similar risk of recurrent venous thromboembolism as patients with a normal genotype (HR 1.3; 95% CI 0.7-2.3).
Why the study?
Does heterozygous carrier status for the G20210A prothrombin gene mutation increase the risk of recurrent venous thromboembolism in patients with a prior DVT or PE?
Population
624 patients referred for previous objectively documented deep venous thrombosis of the legs or pulmonary…
Comparison
Heterozygous carrier status for the G20210A… vs Normal genotype
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
Carrier status should not yet guide anticoagulation duration after VTE; leaves open whether prothrombin testing refines recurrence risk stratification.
Study Design
Type
Cohort (n=624)
Structured PICO
Does heterozygous carrier status for the G20210A prothrombin gene mutation increase the risk of recurrent venous thromboembolism in patients with a prior DVT or PE?
P
Population
624 patients with a previous deep venous thrombosis or pulmonary embolism, analyzed to compare recurrence risk between 52 prothrombin mutation carriers and 283 normal genotype patients.
E
Exposure
Heterozygous carrier status for the G20210A prothrombin gene mutation
C
Comparator
Normal genotype
O
Outcome
Recurrent venous thromboembolismhard clinical
Main Result
Hazard Ratio: 1.3 (95% CI 0.7–2.3)
Heterozygous carriers of the G20210A prothrombin gene mutation do not have a significantly higher risk of recurrent venous thromboembolism compared to patients with a normal genotype, suggesting they should receive a similar duration of oral anticoagulation.
Cite This Study
Stefano et al. (2001) conducted a cohort in Venous thromboembolism (n=624). Heterozygous G20210A prothrombin gene mutation vs. Normal genotype was evaluated on Spontaneous recurrent venous thromboembolism (HR 1.3, 95% CI 0.7-2.3). Heterozygous carriers of the G20210A prothrombin gene mutation had a similar risk of recurrent venous thromboembolism as patients with a normal genotype (HR 1.3; 95% CI 0.7-2.3).